News stories about Neos Therapeutics (NASDAQ:NEOS) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neos Therapeutics earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.3314511889483 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

Neos Therapeutics (NASDAQ NEOS) opened at 8.70 on Thursday. The company’s market capitalization is $244.30 million. Neos Therapeutics has a 52-week low of $4.85 and a 52-week high of $9.60. The stock’s 50 day moving average price is $7.16 and its 200-day moving average price is $7.24.

Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.83) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.83). The company had revenue of $4.91 million for the quarter. Neos Therapeutics had a negative return on equity of 611.78% and a negative net margin of 511.74%. Analysts predict that Neos Therapeutics will post ($3.15) earnings per share for the current fiscal year.

A number of brokerages have issued reports on NEOS. Zacks Investment Research raised shares of Neos Therapeutics from a “hold” rating to a “strong-buy” rating and set a $8.00 price objective for the company in a report on Wednesday, August 23rd. ValuEngine raised shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 12th. Cantor Fitzgerald set a $20.00 price objective on shares of Neos Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 9th. Royal Bank Of Canada set a $12.00 price objective on shares of Neos Therapeutics and gave the company an “outperform” rating in a report on Tuesday, August 8th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $15.00 target price on shares of Neos Therapeutics in a research report on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $13.83.

TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Insider Buying and Selling by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Stock Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related stocks with our FREE daily email newsletter.